Mesoblast has completed treatment of all 350 patients in its pivotal phase 3 trial of rexlemestrocel-L for chronic low back pain caused by inflammatory degenerative disc disease, putting the company on track for top-line results in mid-2027. …
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
August 17, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit -
Taking a stake is not the same as spectating investor risk and expecting a benefit
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News